Investing
Drugmaker Gilead to acquire CymaBay for $4.3 billion
© Reuters. FILE PHOTO: Gilead Sciences is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo
(Reuters) – Gilead Sciences (NASDAQ:) on Monday said it will acquire CymaBay Therapeutics (NASDAQ:) for $4.3 billion, to expand its portfolio of liver disease drugs.
The deal will give Gilead access to CymaBay’s lead drug candidate called seladelpar for the treatment of primary biliary cholangitis, a type of chronic inflammatory liver disease.
CymaBay had submitted a marketing application to the U.S. Food and Drug Administration (FDA) for the drug in December.
Shares of CymaBay were halted ahead of the announcement in premarket hours.
Read the full article here
-
Personal Finance7 days ago
If you are 60 years old, new 401(k) rules could save you money
-
Investing6 days ago
Bank regulator gives BlackRock new deadline on bank stakes, Bloomberg reports By Reuters
-
Side Hustles4 days ago
LA Rental Prices Skyrocketing Despite Price Gouging Laws
-
Side Hustles4 days ago
How to Craft Marketing Campaigns That Reach Multiple Generations
-
Side Hustles2 days ago
What to Do If TikTok is Banned — How to Protect Your Brand
-
Side Hustles6 days ago
FileJump Offers 2TB of Cloud Storage for $70—With No Strings Attached
-
Side Hustles6 days ago
5 AI Books Top Entrepreneurs Are Reading in a Rush for 2025
-
Make Money6 days ago
Grandma’s Fortune: 9 Surprising Heirlooms Worth Serious Money